<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="336153">
  <stage>Registered</stage>
  <submitdate>26/10/2010</submitdate>
  <approvaldate>26/10/2010</approvaldate>
  <actrnumber>ACTRN12610000913077</actrnumber>
  <trial_identification>
    <studytitle>Artesunate-pyronaridine and artemisinin-naphthoquine combination therapies for Papua New Guinean children with uncomplicated malaria infections</studytitle>
    <scientifictitle>Efficacy of artesunate-pyronaridine and artemisinin-naphthoquine combination therapies compared with standard artemether-lumefantrine in children from Papua New Guinea with uncomplicated malaria who are monitored for recurrent malaria over 42 days post-treatment</scientifictitle>
    <utrn>U1111-1117-5907</utrn>
    <trialacronym>Standard Treatment Trial II</trialacronym>
    <secondaryid>Nil</secondaryid>
    <secondaryid>Nil known</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Malaria</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Artesunate-pyronaridine (Pyramax) as artesunate 3 mg/kg and pyronaridine base 10 mg/kg once-daily for three days or artemisinin-naphthoquine (Arco) as artemisinin 20 mg/kg and naphthoquine phosphate 8 mg/kg once-daily for three days. Both drug regimens will be given orally with water. Doses will be calculated from body weight to the nearest whole sachet of granules (Pyramax) or tablets (Arco).</interventions>
    <comparator>Artemether-lumefantrine (Novartis Pharma, Basel, Switzerland) as artemether 1.7 mg/kg and lumefantrine 10 mg/kg twice-daily for three days given orally with milk. Doses will be calculated from body weight to the nearest whole tablet.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Recrudescent Plasmodium falciparum after correction for re-infections using PCR genotyping of polymorphic parasite loci in children with falciparum malaria</outcome>
      <timepoint>Within 42 days after initiation of treatment</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Appearance of any Plasmodium vivax parasitaemia on blood smear after treatment for vivax malaria.</outcome>
      <timepoint>Within 42 days after initiation of treatment</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Reappearance of PCR-uncorrected P. falciparum parasitemia on blood smear after treatment of falciparum malaria</outcome>
      <timepoint>Within 42 days after initiation of treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Appearance of any P. vivax parasitemia on blood smear after treatment of falciparum malaria</outcome>
      <timepoint>Within 42 days after initiation of treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Appearance of P. falciparum gametocytes on blood smear after treatment of falciparum malaria</outcome>
      <timepoint>Within 42 days after initiation of treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Appearance of P. vivax gametocytes on blood smear within 42 daysa fter treatment of vivax malaria</outcome>
      <timepoint>Within 42 days after initiation of treatment</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Children with an axillary temperature &gt;37.5 degrees Centigrade or fever during the previous 24 hours with either P. falciparum (&gt;1000 asexual parasites per microlitre whole blood) or P. vivax (&gt;250 per microlitre) on blood smear microscopy</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>5</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Features of severity, treatment with a study drug or other antimalarial in the previous 28 days, clinical or laboratory evidence of another infection or co-morbidity including malnutrition</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Eligible children will be enrolled at participating field sites after parental informed consent has been obtained. The study is open label but randomisation will be by computer generated code contained in a sealed envelope to be opened at the time of recruitment.</concealment>
    <sequence>Simple randomisation by using a randomization table created by a computer software (i.e., computerised sequence generation)</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3 / Phase 4</phase>
    <anticipatedstartdate>1/11/2010</anticipatedstartdate>
    <actualstartdate>2/04/2012</actualstartdate>
    <anticipatedenddate>30/04/2014</anticipatedenddate>
    <actualenddate>24/04/2013</actualenddate>
    <samplesize>637</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up complete</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Papua New Guinea</country>
      <state>Madang</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Papua New Guinea</country>
      <state>East Sepik</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Papua New Guinea</country>
      <state>East New Britain</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>University of Western Australia</primarysponsorname>
    <primarysponsoraddress>School of Medicine and Pharmacology, Fremantle Hospital, PO Box 480, Fremantle, Western Australia 6959</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>National Health and Medical Research Council</fundingname>
      <fundingaddress>GPO Box 1421
Canberra ACT 2601</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Other</sponsortype>
      <sponsorname>Papua New Guinea Insitute of Medical Research</sponsorname>
      <sponsoraddress>P O Box 60, Goroka, Eastern Highlands Province 411</sponsoraddress>
      <sponsorcountry>Papua New Guinea</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>We recently found that the WHO-recommended combination antimalarial therapy artemether-lumefantrine and the candidate regimen dihydroartemisinin-piperaquine were not fully effective for both falciparum and vivax malaria in young Papua New Guinean children, a group at high risk of complications and death. We plan to study two new combinations (artesunate-pyronaridine and artemisinin-naphthoquine) in the hope that at least one will prove superior and be used in treatment programs in PNG and similar countries.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Medical Research Advisory Committee</ethicname>
      <ethicaddress>Government of PNG, Department of Health, PO Box 807, Waigani NCD 131</ethicaddress>
      <ethicapprovaldate>28/06/2010</ethicapprovaldate>
      <hrec>MRAC 10.39</hrec>
      <ethicsubmitdate />
      <ethiccountry>Papua New Guinea</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Human Research Ethics Committee</ethicname>
      <ethicaddress>University of Western Australia, Crawley 6009</ethicaddress>
      <ethicapprovaldate>7/05/2010</ethicapprovaldate>
      <hrec>RA/4/1/4125</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Timothy Davis</name>
      <address>University of Western Australia, School of Medicine and Pharmacology, Fremantle Hospital, PO Box 480, Fremantle, Western Australia 6959</address>
      <phone>+618 9431 3229</phone>
      <fax>+618 9431 2977</fax>
      <email>tim.davis@uwa.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Timothy Davis</name>
      <address>University of Western Australia, School of Medicine and Pharmacology, Fremantle Hospital, PO Box 480, Fremantle, Western Australia 6959</address>
      <phone>+618 9431 3229</phone>
      <fax>+618 9431 2977</fax>
      <email>tim.davis@uwa.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Timothy Davis</name>
      <address>University of Western Australia, School of Medicine and Pharmacology, Fremantle Hospital, PO Box 480, Fremantle, Western Australia 6959</address>
      <phone>+618 9431 3229</phone>
      <fax>+618 9431 2977</fax>
      <email>tim.davis@uwa.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Timothy Davis</name>
      <address>School of Medicine and Pharmacology, University of Western Australia, Fremantle Hospital, PO Box 480, Fremantle 6959, Western Australia, Australia</address>
      <phone>+618 9431 3229</phone>
      <fax />
      <email>tim.davis@uwa.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>